Efficacy and Safety of Tazarotene Gel in Nail Psoriasis (NCT02235480) | Clinical Trial Compass
CompletedPhase 2
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
Germany66 participantsStarted 2014-02
Plain-language summary
The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Key inclusion criteria:
* Mild to moderate nail psoriasis on at least one fingernail
Exclusion Criteria:
Key exclusion criteria:
* any other skin condition, with a potential to affect the nails or to interfere with evaluation of the disease;
* history of hypersensitivity to retinoids or to other components of the trial medication
* topical treatment of nails with antipsoriatics in the 4 weeks preceding the treatment phase;
* systemic treatment of psoriasis within the three months before the treatment phase of the trial or during the trial
* intralesional steroid injection before the treatment phase of the trial
* phototherapy before the treatment phase of the trial;
* any chronic infection or condition capable of interfering with the conduct of the trial;
* evidence of drug or alcohol abuse;
* symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks preceding the treatment phase of the trial;
* participation in another clinical trial within the last 4 weeks prior to first treatment in this clinical trial;
* pregnancy or nursing;
What they're measuring
1
% reduction in the Nail Psoriasis Severity Index ( NAPSI )